• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    4/14/23 1:30:59 PM ET
    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Petros Pharma (NASDAQ:PTPI) stock increased by 513.9% to $6.2 during Friday's regular session. Trading volume for this security as of 13:30 EST is 58.4 million, which is 381878.2% of its average full-day volume over the last 100 days. The company's market cap stands at $12.9 million.
    • CNS Pharma (NASDAQ:CNSP) shares moved upwards by 64.94% to $1.13. Trading volume for CNS Pharma's stock is 16.1 million as of 13:30 EST. This is 5779.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • LumiraDx (NASDAQ:LMDX) stock increased by 34.03% to $0.77. The current volume of 504.0K shares is 257.9% of LumiraDx's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $244.5 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 32.11% to $1.44. As of 13:30 EST, this security is trading at a volume of 11.0 million shares, making up 5390.8% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 30.84% to $0.69. BIMI Intl Medical's stock is trading at a volume of 583.5K shares as of 13:30 EST. This is 1110.5% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares increased by 25.97% to $2.9. The company's market cap stands at $4.4 million.

    Losers

    • Pear Therapeutics (NASDAQ:PEAR) shares decreased by 38.8% to $0.07 during Friday's regular session. The current volume of 56.9 million shares is 941.3% of Pear Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $10.3 million.
    • GlucoTrack (NASDAQ:GCTK) stock decreased by 31.76% to $0.94. GlucoTrack's stock is trading at a volume of 2.3 million shares as of 13:30 EST. This is 95.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.4 million.
    • ViewRay (NASDAQ:VRAY) shares fell 27.87% to $1.32. As of 13:30 EST, this security is trading at a volume of 13.4 million shares, making up 939.4% of its average full-day volume over the last 100 days. The company's market cap stands at $239.9 million.
    • Predictive Oncology (NASDAQ:POAI) shares decreased by 27.05% to $0.36. Predictive Oncology's stock is trading at a volume of 37.0 million shares as of 13:30 EST. This is 4928.3% of its average full-day volume over the last 100 days. The company's market cap stands at $28.3 million.
    • Catalent (NYSE:CTLT) shares decreased by 26.15% to $46.76. Trading volume for this security as of 13:30 EST is 15.9 million, which is 725.8% of its average full-day volume over the last 100 days. The company's market cap stands at $8.4 billion.
    • Biophytis (NASDAQ:BPTS) stock fell 25.22% to $3.44. The current volume of 67.3K shares is 77.5% of Biophytis's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $7.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BIMI
    $BPTS
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Predictive Oncology Inc.
    $POAI
    8/19/2024$3.00Buy
    H.C. Wainwright
    Catalent Inc.
    $CTLT
    11/16/2023$45.00 → $53.00Neutral → Outperform
    Robert W. Baird
    Catalent Inc.
    $CTLT
    9/5/2023$62.00Hold → Buy
    Argus
    Catalent Inc.
    $CTLT
    7/20/2023$43.00Equal Weight
    Wells Fargo
    Catalent Inc.
    $CTLT
    7/5/2023$45.00Neutral
    JP Morgan
    Catalent Inc.
    $CTLT
    6/14/2023$45.00 → $44.00Buy → Hold
    Jefferies
    Catalent Inc.
    $CTLT
    5/22/2023$90.00 → $45.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sycoff Drew bought $230,000 worth of shares (182,540 units at $1.26), increasing direct ownership by 7% to 2,951,258 units (SEC Form 4)

    4 - GlucoTrack, Inc. (0001506983) (Issuer)

    4/24/24 6:31:49 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Gumulka Jerzy bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 345% to 43,006 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:28:10 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evans Carl Anthony bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 26,666% to 33,458 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:56 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

    H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    8/19/24 6:55:24 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Catalent upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Catalent from Neutral to Outperform and set a new price target of $53.00 from $45.00 previously

    11/16/23 7:14:33 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    SEC Filings

    View All

    SEC Form S-8 filed by CNS Pharmaceuticals Inc.

    S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    2/27/26 5:22:40 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/19/26 8:00:48 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.

    SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    2/17/26 10:50:32 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Graff Jeremy R. was granted 133,333 shares, increasing direct ownership by 54% to 381,644 units (SEC Form 4)

    4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    1/16/26 4:13:58 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    1/6/26 5:30:07 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Levin Rami

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    1/2/26 5:01:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

         Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investi

    2/18/26 8:15:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

             This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temo

    2/3/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

    RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack's competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. The three patents protect key technologies in Glucotra

    1/29/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

    RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man

    10/29/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 4:35:03 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CNS Pharmaceuticals Inc.

    SC 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    11/14/24 3:58:53 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BIMI
    $BPTS
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care